Clinical Alliance for Research & Education - Infectious Diseases, LLC.
With
GlaxoSmithKline
Open-label, multicenter study of ABC/3TC + ATV in subjects who have completed at least 24 weeks of treatment on ABC/3TC+ATV/RTV as their first line regimen and have plasma HIV-1 RNA \<50 copies/mL at entry
Age
18–any
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Currently taking abacavir/lamivudine (Epzicom) in combination with atazanavir (Reyataz) boosted with ritonavir (Norvir) as first antiretroviral regimen
Viral load \<50 copies/ml
You may not be if
Viral load \>50 copies/ml
Having taken more than one antiretroviral regimen
Clareo Health | SHARE: Simple HAART With Abacavir, Reyataz, and Epivir
